GLP-1, OBESITY & METABOLIC
GLP-1, Obesity, and Metabolic Research Supported by Endocrinology Expertise
Sequoia brings obesity and Type 2 diabetes research experience to GLP-1 and related metabolic programs, including studies involving patients with cardiometabolic and renal comorbidities. Experienced endocrinologist investigators and access to relevant patient populations help sponsors confidently advance metabolic programs.
GLP-1, Obesity & Metabolic Experience
Sequoia has completed over 40 obesity and Type 2 diabetes studies, supported by investigators with metabolic research experience involving patients with chronic kidney disease, hypertension, and heart failure. Our investigators also bring expertise in GLP-1 and related metabolic protocols involving complex cardiometabolic and renal populations.
- Obesity
- Type 1 and Type 2 Diabetes
- Weight Management
- Obesity with Heart Failure
- Obesity with Hypertension
- Obesity with Chronic Kidney Disease
- Sarcopenic Obesity
- Cardiometabolic Conditions
Patient Access & Study Execution
Metabolic studies require access to well-characterized patient populations and a realistic recruitment plan. Sequoia’s investigators bring established patient populations to the network, supported by a centralized recruitment infrastructure and local research teams to assess protocol feasibility and identify pre-qualified participants.
40+
completed obesity and Type 2 diabetes studies
17,000+
patients with BMI over 27
95%+
Retention above 95% at the Houston sites
15–25+
participants typically enrolled per obesity study
- 40,000+ participant research database and 65,000+ active patient charts
- 20+ dedicated study recruiters, each handling approximately 100 calls per day
- 75–80% Hispanic and Black patient population across Houston sites
Supporting Investigators
Dr. Damaris Vega is a board-certified endocrinologist with more than 20 years of clinical research experience. Her work in obesity and metabolic research includes patient populations with chronic kidney disease, hypertension, and heart failure, and she maintains an active endocrinology practice alongside her research.
Dr. Rocio Harbison is a board-certified endocrinologist with 10 years of clinical research experience in obesity studies across patients with chronic kidney disease, hypertension, and heart failure. She supports metabolic research across Sequoia’s network.
Dr. Yaser Mounla is a board-certified endocrinologist with 25 years of clinical experience in diabetes, thyroid, and other endocrine disorders. His endocrinology expertise supports Sequoia’s metabolic research across obesity, diabetes, and related endocrine studies.
Protocol-Specific Capabilities
Depending on protocol requirements, Sequoia provides access to:
Inpatient capabilities
Onsite pharmacy
PK/PD support
Temperature-controlled investigational product storage
Retention support for studies requiring extended treatment and follow-up
NETWORK
Backed by the Sequoia Network
Every vaccine study benefits from shared operational support, standardized quality systems, and collaborative investigator expertise.
Five FDA inspections with zero Form 483 findings reflect Sequoia's commitment to consistent quality across every study.
Discuss Your GLP-1, Obesity, or Metabolic Study
Connect with Sequoia to explore investigator fit, patient access, and feasibility for your next metabolic clinical trial.
Frequently asked questions
What metabolic conditions does Sequoia study?
Sequoia’s metabolic research covers obesity, Type 1 and Type 2 diabetes, weight management, and obesity with comorbidities such as heart failure, hypertension, chronic kidney disease, and sarcopenic obesity.
Does Sequoia have GLP-1 study experience?
Yes. Sequoia has completed over 40 obesity and Type 2 diabetes studies, supported by board-certified endocrinologist investigators with experience in GLP-1 and related metabolic protocols.
How does Sequoia support participant retention on long metabolic studies?
Sequoia’s Houston sites maintain retention rates above 95%. Our investigators see participants in their clinical practices, supporting continuity and follow-up throughout each study.
Which investigators support metabolic studies?
Metabolic studies are supported by Dr. Damaris Vega, Dr. Rocio Harbison, Dr. Yaser Mounla, and Sequoia’s growing network of investigators, matched to each protocol’s therapeutic focus and patient population.